All Stories

  1. Synthesis and Application of a Glucoconjugated Organometallic Rhenium Complex as an IR Imaging Probe for Glycolytic Cancer Cells
  2. Identification of a Possible Endocannabinoid-Mediated Mechanism of Action of Cetylated Fatty Acids
  3. A patent review of lactate dehydrogenase inhibitors (2014–present)
  4. Effects of lactate dehydrogenase A and GLUT1 inhibition on human endothelial cell migration in relation to their intracellular nucleotide pool
  5. Evaluation of the combination of gemcitabine, carboplatin, and lactate dehydrogenase A inhibitor on malignant mesothelioma
  6. The Benzoylpiperidine Fragment as a Privileged Structure in Medicinal Chemistry: A Comprehensive Review
  7. Sirtuin 1-activating derivatives belonging to the anilinopyridine class displaying in vivo cardioprotective activities
  8. Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing
  9. Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma
  10. Sirtuin 1-Activating Compounds: Discovery of a Class of Thiazole-Based Derivatives
  11. MAGL inhibitor NanoMicellar formulation (MAGL-NanoMicellar) for the development of an antiglaucoma eye drop
  12. New Synthetic Analogues of Natural Polyphenols as Sirtuin 1-Activating Compounds
  13. The effect of lactate dehydrogenase-A inhibition on intracellular nucleotides and mitochondrial respiration in pancreatic cancer cells
  14. New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy
  15. Monoacylglycerol lipase (MAGL) inhibitors based on a diphenylsulfide-benzoylpiperidine scaffold
  16. Discovery of Monoacylglycerol Lipase (MAGL) Inhibitors Based on a Pharmacophore-Guided Virtual Screening Study
  17. An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present)
  18. Glycoconjugated Metal Complexes as Cancer Diagnostic and Therapeutic Agents
  19. Discovery of a new ATP-citrate lyase (ACLY) inhibitor identified by a pharmacophore-based virtual screening study
  20. Synthesis and Biological Evaluation of New Glycoconjugated LDH Inhibitors as Anticancer Agents
  21. First-of-its-kind STARD3 Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent
  22. First Examples of H2S-Releasing Glycoconjugates: Stereoselective Synthesis and Anticancer Activities
  23. Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors
  24. Activators of Sirtuin-1 and their Involvement in Cardioprotection
  25. An Update on Patents Covering Agents That Interfere with the Cancer Glycolytic Cascade
  26. Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors
  27. A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017)
  28. Correction to Constituents of Polygala flavescens ssp. flavescens and Their Activity as Inhibitors of Human Lactate Dehydrogenase
  29. Constituents of Polygala flavescens ssp. flavescens and Their Activity as Inhibitors of Human Lactate Dehydrogenase
  30. Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer
  31. Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors
  32. Immune by Heart: Unexpected Observations Inspiring Perspective Therapeutic/Preventive Strategies against Cancer
  33. Risks and benefits related to alimentary exposure to xenoestrogens
  34. Anticancer agents interacting with membrane glucose transporters
  35. Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase
  36. Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model
  37. Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents
  38. CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1 H )-one-3-carboxamides
  39. Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
  40. An update on therapeutic opportunities offered by cancer glycolytic metabolism
  41. Identification and characterization of a new reversible MAGL inhibitor
  42. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways
  43. Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells
  44. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
  45. Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor
  46. Identification of New Fyn Kinase Inhibitors Using a FLAP-Based Approach
  47. Small-molecule inhibitors of human LDH5
  48. Estrogen receptor ligands: a patent review update
  49. Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors
  50. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds
  51. Anticancer Agents That Counteract Tumor Glycolysis
  52. Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5
  53. N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation
  54. Carbazole-containing arylcarboxamides as BACE1 inhibitors
  55. Curaxins: A New Family of Non-genotoxic Multitargeted Anticancer Agents
  56. Antiproliferative Activity and Cell Cycle Analysis of 2-(3,5-Dihydroxyphenyl)-6-Hydroxybenzothiazole on MCF-7 Breast and HCT-15 Colon Cancer Cell Lines
  57. Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes
  58. Discovery of N -Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells
  59. Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5)
  60. BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides
  61. Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties
  62. Biphenyl-Derivatives Possessing Tertiary Amino Groups as β-Secretase (BACE1) Inhibitors
  63. Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells
  64. Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials
  65. Estrogen receptor β ligands: Recent advances and biomedical applications
  66. Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours
  67. QSAR models for predicting enzymatic hydrolysis of new chemical entities in ‘soft-drug’ design
  68. Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen Receptor β
  69. Spirocyclic Benzopyran-Based Derivatives as New Anti-ischemic Activators of Mitochondrial ATP-Sensitive Potassium Channel
  70. α-Naphthylaminopropan-2-ol Derivatives as BACE1 Inhibitors
  71. Monoaryl-Substituted Salicylaldoximes as Ligands for Estrogen Receptor β
  72. Evaluation of the NO-releasing properties of NO-donor linkers
  73. Synthesis and Affinity Evaluation for AT1 Receptor of Phenylsalicylaldoxime-Derivatives Structurally Related to Sartans
  74. Metabolically labile cannabinoid esters: A ‘soft drug’ approach for the development of cannabinoid-based therapeutic drugs
  75. New Benzopyran-Based Openers of the Mitochondrial ATP-Sensitive Potassium Channel with Potent Anti-Ischemic Properties
  76. Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes
  77. New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite:  Design, Synthesis, and Biopharmacological Properties
  78. N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation
  79. Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)-Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase Inhibition
  80. Synthesis of a Resveratrol Analogue with High Ceramide-Mediated Proapoptotic Activity on Human Breast Cancer Cells
  81. Variously Substituted (Phosphonoacetamido)Oxy Analogues of Geranylgeranyl Diphosphate (GGdP) as GGdP-transferase (GGTase) Inhibitors and Antiproliferative Agents
  82. Stable propylphosphonic acid analogues of geranylgeranyl diphosphate possessing inhibitory activity on geranylgeranyl protein transferase
  83. Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors
  84. NO-Sartans:  A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs
  85. Diaryl-substituted salicyl- and anthranyl-ketoximes as potential estrogen receptor ligands
  86. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2)
  87. Synthesis and COX-2 inhibitory properties of N-phenyl- and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene and isoxazole analogs
  88. Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity
  89. Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity
  90. Novel Estrogen Receptor Ligands Based on an Anthranylaldoxime Structure:  Role of the Phenol-Type Pseudocycle in the Binding Process
  91. Synthesis, binding affinity, and transcriptional activity of hydroxy- and methoxy-Substituted 3,4-Diarylsalicylaldoximes on estrogen receptors α and β
  92. Ceramide analogues in apoptosis: a new strategy for anticancer drug development
  93. Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring
  94. New N - n -Propyl-Substituted 3-Aryl- and 3-Cyclohexylpiperidines as Partial Agonists at the D 4 Dopamine Receptor
  95. Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity
  96. 4-[6-(Dansylamino)hexylamino]-7-methyl-2-phenyl-1,8-naphthyridine as a new potential fluorescent probe for studying A1-adenosine receptor
  97. Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties
  98. 7-Nitrobenzofurazan (NBD) derivatives of 5′-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A3 adenosine receptors
  99. Design, Synthesis, and Characterization of the Antitumor Activity of Novel Ceramide Analogues †
  100. Salicylaldoxime Moiety as a Phenolic “A-Ring” Substitute in Estrogen Receptor Ligands
  101. Purification, Enzymatic Characterization, and Inhibition of the Z-Farnesyl Diphosphate Synthase from Mycobacterium tuberculosis
  102. Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand
  103. Synthesis and antiviral properties of novel analogues of monophosphate and diphosphate bioactive forms of acyclovir
  104. Synthesis and antiviral properties of 9-[(2-methyleneaminoxyethoxy)methyl]guanine derivatives as novel Acyclovir analogues
  105. Crystallographic evidence for the electronic distribution in (2,4-cyclopentadien-1-ylidenehydrazono)triphenylphosphorane
  106. Three-Component Synthesis of Substituted η 5 -Cyclopentadienyltricarbonylrhenium Complexes:  Scope, Limitations, and Mechanistic Interpretations
  107. A Polymer-Supported Phosphazine as a Stable and Practical Reagent in the Three-Component Synthesis of Substituted (Cyclopentadienyl)tricarbonylrhenium Complexes
  108. Boronic Acids in the Three-Component Synthesis of Carbon-Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes
  109. A Convenient Three-Component Synthesis of Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes
  110. Heterogeneous asymmetric epoxidation of unfunctionalized olefins catalyzed by polymer-bound (salen)manganese complexes
  111. Polymer-bound chiral (salen)Mn(III) complex as heterogeneous catalyst in rapid and clean enantioselective epoxidation of unfunctionalised olefins
  112. Efficient application of lipase-catalyzed transesterification to the resolution of γ-hydroxy ketones
  113. Asymmetric Synthesis of the Dihydroisocoumarin Moiety of AI-77-B via Copper-Mediated Cross-Coupling and Sharpless Asymmetric Dihydroxylation
  114. Anomalous Face-Selectivity in Sharpless Asymmetric Dihydroxylation of o -Allylbenzamides
  115. Aromatic substituent effect on the stereoselectivity of the gas-phase acid-induced ring opening in 9,10-oxides derived from trans-1,2,3,4,4a,10a-hexahydrophenanthrene